Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update

Rhea-AI Summary

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology firm focusing on tolerogenic therapies, announced a conference call scheduled for August 4, 2022, at 8:30 a.m. ET to discuss its financial results for Q2 2022 and provide a business update. The call will be accessible via phone, with a replay available for one week. Selecta aims to leverage its ImmTOR® platform to enhance gene therapies and treat autoimmune diseases, positioning itself as a clinical-stage innovator in the space.

Positive

• Selecta's ImmTOR® platform shows potential to enhance efficacy of biologic therapies.
• The company has several proprietary and partnered programs in its pipeline focused on enzyme therapies and gene therapies.

Negative

• None.

WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that it plans to host a conference call on Thursday, August 4, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10157873. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com

FAQ

When is Selecta Biosciences' earnings call for Q2 2022?

The earnings call is scheduled for August 4, 2022, at 8:30 a.m. ET.

What is the focus of Selecta Biosciences?

Selecta is focused on developing tolerogenic therapies using its ImmTOR® platform for autoimmune diseases and enhancing gene therapies.

How can I access Selecta Biosciences' conference call?

The live call can be accessed by dialing (844) 845-4170 for domestic or (412) 717-9621 for international callers.

What can investors expect from Selecta's upcoming business update?

Investors can expect insights into Q2 financial results and updates on the company's business strategy and pipeline.